BALAD score predicts the recurrence and survival in the patients who underwent initial hepatectomy for HCC

IF 2.3 4区医学 Q3 ONCOLOGY

Surgical Oncology-Oxford Pub Date : 2024-07-02 DOI:10.1016/j.suronc.2024.102097

Shigeki Nakagawa, Hiromitsu Hayashi, Rumi Itoyama, Yuki Kitano, Kosuke Mima, Hirohisa Okabe, Hideo Baba

{"title":"BALAD score predicts the recurrence and survival in the patients who underwent initial hepatectomy for HCC","authors":"Shigeki Nakagawa, Hiromitsu Hayashi, Rumi Itoyama, Yuki Kitano, Kosuke Mima, Hirohisa Okabe, Hideo Baba","doi":"10.1016/j.suronc.2024.102097","DOIUrl":null,"url":null,"abstract":"<div><h3>Backgrounds</h3><p>Several studies have indicated that BALAD score which includes the HCC tumor markers of HCC, AFP, AFP-L3%, DCP, and serum albumin and bilirubin value were good predictors of HCC patients for all treatment modalities. In this study, we aim to clarify the impact of BALAD score as the prognostic factor for HCC patients after curative surgery.</p></div><div><h3>Methods</h3><p>This study investigated 578 patients who underwent hepatectomy for HCC between January 2003 and May 2013. Cumulative recurrence rate, overall survival (OS), and clinicopathological parameters were analyzed according to the level of BALAD score.</p></div><div><h3>Results</h3><p>In patients with higher BALAD score, recurrence rate and OS was poor (p = 0.0015 and p < 0.0001, respectively). Multivariate analyses revealed independent risk factors for recurrence to be male (hazard ratio [HR] 1.52, <em>P</em> = 0.011), HCV-antibody positive (HR 1.33, <em>P</em> = 0.019), multiple tumors (HR 2.16, <em>P</em> < 0.0001), microvascular invasion (HR 1.45, <em>P</em> = 0.0035) and higher BALAD score (RR 1.70, <em>P</em> = 0.015). The independent risk factors for OS were multiple tumors (HR 1.52, <em>P</em> = 0.014), microvascular invasion (HR 1.53, <em>P</em> = 0.012), and higher BALAD score (RR 2.51, <em>P</em> = 0.0012).</p></div><div><h3>Conclusion</h3><p>BALAD score is associated with high recurrence rate and poor overall survival of the patients who underwent curative liver resection for HCC.</p></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Surgical Oncology-Oxford","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0960740424000653","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Backgrounds

Several studies have indicated that BALAD score which includes the HCC tumor markers of HCC, AFP, AFP-L3%, DCP, and serum albumin and bilirubin value were good predictors of HCC patients for all treatment modalities. In this study, we aim to clarify the impact of BALAD score as the prognostic factor for HCC patients after curative surgery.

Methods

This study investigated 578 patients who underwent hepatectomy for HCC between January 2003 and May 2013. Cumulative recurrence rate, overall survival (OS), and clinicopathological parameters were analyzed according to the level of BALAD score.

Results

In patients with higher BALAD score, recurrence rate and OS was poor (p = 0.0015 and p < 0.0001, respectively). Multivariate analyses revealed independent risk factors for recurrence to be male (hazard ratio [HR] 1.52, P = 0.011), HCV-antibody positive (HR 1.33, P = 0.019), multiple tumors (HR 2.16, P < 0.0001), microvascular invasion (HR 1.45, P = 0.0035) and higher BALAD score (RR 1.70, P = 0.015). The independent risk factors for OS were multiple tumors (HR 1.52, P = 0.014), microvascular invasion (HR 1.53, P = 0.012), and higher BALAD score (RR 2.51, P = 0.0012).

Conclusion

BALAD score is associated with high recurrence rate and poor overall survival of the patients who underwent curative liver resection for HCC.

查看原文本刊更多论文

BALAD 评分可预测初次接受肝癌切除术患者的复发率和存活率

背景多项研究表明，包括HCC、AFP、AFP-L3%、DCP、血清白蛋白和胆红素值等HCC肿瘤标志物在内的BALAD评分是HCC患者接受所有治疗方式的良好预测指标。本研究旨在明确 BALAD 评分作为治愈性手术后预后因素对 HCC 患者的影响。方法本研究调查了 2003 年 1 月至 2013 年 5 月间接受肝切除术治疗的 578 例 HCC 患者。结果 BALAD评分越高的患者，复发率和OS越低（分别为P = 0.0015和P < 0.0001）。多变量分析显示，男性（危险比 [HR] 1.52，P = 0.011）、HCV 抗体阳性（HR 1.33，P = 0.019）、多发肿瘤（HR 2.16，P < 0.0001）、微血管侵犯（HR 1.45，P = 0.0035）和 BALAD 评分较高（RR 1.70，P = 0.015）是复发的独立危险因素。多发肿瘤（HR 1.52，P = 0.014）、微血管侵犯（HR 1.53，P = 0.012）和较高的BALAD评分（RR 2.51，P = 0.0012）是影响OS的独立危险因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Surgical Oncology-Oxford 医学-外科

CiteScore

4.50

自引率

0.00%

发文量

169

审稿时长

38 days

期刊介绍： Surgical Oncology is a peer reviewed journal publishing review articles that contribute to the advancement of knowledge in surgical oncology and related fields of interest. Articles represent a spectrum of current technology in oncology research as well as those concerning clinical trials, surgical technique, methods of investigation and patient evaluation. Surgical Oncology publishes comprehensive Reviews that examine individual topics in considerable detail, in addition to editorials and commentaries which focus on selected papers. The journal also publishes special issues which explore topics of interest to surgical oncologists in great detail - outlining recent advancements and providing readers with the most up to date information.